<p>Moderna is scaling back expectations for the number of Covid-19 vaccine deliveries it expects to make this year and the revenue it will record from them.</p>.<p>The drugmaker said on Thursday that longer delivery lead times for exports and a temporary impact from expanding its fill-finish capacity may shift some deliveries to early 2022.</p>.<p>The company now expects full-year, 2021 product sales of between $15 billion and $18 billion.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/international/moderna-says-fda-needs-more-time-to-complete-review-of-its-covid-19-shot-for-adolescents-1046110.html">Moderna says FDA needs more time to complete review of its Covid-19 shot for adolescents</a></strong></p>.<p>That's down from a prediction for $20 billion in sales that it made in August.</p>.<p>Moderna's Covid-19 vaccine is the only product the drugmaker has on the market. It brought in $4.81 billion in sales during the third quarter, up from $4.2 billion the previous quarter.</p>.<p>The Cambridge, Massachusetts, company also reported on Thursday third-quarter results that missed expectations.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/business/moderna-covid-19-shot-could-start-being-used-in-children-teens-within-weeks-ceo-says-1044875.html">Moderna Covid-19 shot could start being used in children, teens 'within weeks,' CEO says</a></strong></p>.<p>Company shares fell almost 11% before the opening bell.</p>.<p>Moderna Inc. makes one of three Covid-19 vaccines currently being used in the United States.</p>.<p>The others are made by Pfizer Inc. and Johnson & Johnson.</p>.<p><strong>Watch the latest DH Videos here:</strong></p>
<p>Moderna is scaling back expectations for the number of Covid-19 vaccine deliveries it expects to make this year and the revenue it will record from them.</p>.<p>The drugmaker said on Thursday that longer delivery lead times for exports and a temporary impact from expanding its fill-finish capacity may shift some deliveries to early 2022.</p>.<p>The company now expects full-year, 2021 product sales of between $15 billion and $18 billion.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/international/moderna-says-fda-needs-more-time-to-complete-review-of-its-covid-19-shot-for-adolescents-1046110.html">Moderna says FDA needs more time to complete review of its Covid-19 shot for adolescents</a></strong></p>.<p>That's down from a prediction for $20 billion in sales that it made in August.</p>.<p>Moderna's Covid-19 vaccine is the only product the drugmaker has on the market. It brought in $4.81 billion in sales during the third quarter, up from $4.2 billion the previous quarter.</p>.<p>The Cambridge, Massachusetts, company also reported on Thursday third-quarter results that missed expectations.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/business/moderna-covid-19-shot-could-start-being-used-in-children-teens-within-weeks-ceo-says-1044875.html">Moderna Covid-19 shot could start being used in children, teens 'within weeks,' CEO says</a></strong></p>.<p>Company shares fell almost 11% before the opening bell.</p>.<p>Moderna Inc. makes one of three Covid-19 vaccines currently being used in the United States.</p>.<p>The others are made by Pfizer Inc. and Johnson & Johnson.</p>.<p><strong>Watch the latest DH Videos here:</strong></p>